Two phase 3 trials -- one for the cancer-fighting drug Iniparib and the other for Otamixaban, a therapy designed for use in treating coronary disease -- have been terminated due to a lack of results, Sanofi (NYSE:SNY) announced today.
In the Iniparib study, newly diagnosed cell lung patients were treated with the drug in conjunction with chemotherapy. According to Sanofi, "There were no clinically meaningful differences in the main safety parameters," compared to patients who received chemotherapy alone. Ending development of Iniparib will result in a $235 million non-cash charge recognized on Sanofi's June 30, 2013 consolidated balance sheet.
The results for the anticoagulant Otamixaban were also unsuccessful and the drug did not "meet its primary endpoint of superiority over current therapy," according to Sanofi. Following the study, it was determined that the investigational program for Otamixaban will also be discontinued.
Fool contributor Tim Brugger has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.